Resumen de acción AFX
Carl Zeiss Meditec AG opera como empresa de tecnología médica en Alemania, el resto de Europa, Norteamérica y Asia.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en AFX a partir de nuestros controles de riesgos.
Competidores de Carl Zeiss Meditec AG
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €93.90 |
| 52 Week High | €123.75 |
| 52 Week Low | €72.60 |
| Beta | 0.90 |
| 1 Month Change | -12.16% |
| 3 Month Change | -11.37% |
| 1 Year Change | -16.24% |
| 3 Year Change | -31.11% |
| 5 Year Change | 8.37% |
| Change since IPO | 168.29% |
Noticias y actualizaciones recientes
Is There Now An Opportunity In Carl Zeiss Meditec AG (ETR:AFX)?
Mar 24
Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Mar 11Recent updates
Is There Now An Opportunity In Carl Zeiss Meditec AG (ETR:AFX)?
Mar 24Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Mar 11Slowing Rates Of Return At Carl Zeiss Meditec (ETR:AFX) Leave Little Room For Excitement
Feb 12Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
Jan 29What Does Carl Zeiss Meditec AG's (ETR:AFX) Share Price Indicate?
Dec 08Carl Zeiss Meditec (ETR:AFX) Is Experiencing Growth In Returns On Capital
Nov 08Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 37% Above Its Share Price
Oct 24Is Carl Zeiss Meditec (ETR:AFX) A Risky Investment?
Sep 24Should You Investigate Carl Zeiss Meditec AG (ETR:AFX) At €85.72?
Sep 08Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
Jul 24We Like These Underlying Return On Capital Trends At Carl Zeiss Meditec (ETR:AFX)
Jun 19Should You Think About Buying Carl Zeiss Meditec AG (ETR:AFX) Now?
Jun 06Is Now The Time To Put Carl Zeiss Meditec (ETR:AFX) On Your Watchlist?
May 22Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 24% Below Its Share Price
Apr 19Carl Zeiss Meditec (ETR:AFX) Has A Pretty Healthy Balance Sheet
Feb 26Carl Zeiss Meditec's (ETR:AFX) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 10Here's Why We Think Carl Zeiss Meditec (ETR:AFX) Is Well Worth Watching
Jan 28Carl Zeiss Meditec (ETR:AFX) Has Announced That It Will Be Increasing Its Dividend To €1.10
Jan 12Carl Zeiss Meditec (ETR:AFX) Will Pay A Larger Dividend Than Last Year At €1.10
Dec 29Carl Zeiss Meditec (ETR:AFX) Has Announced That It Will Be Increasing Its Dividend To €1.10
Dec 14What Is Carl Zeiss Meditec AG's (ETR:AFX) Share Price Doing?
Nov 04Calculating The Intrinsic Value Of Carl Zeiss Meditec AG (ETR:AFX)
Oct 18Investors Will Want Carl Zeiss Meditec's (ETR:AFX) Growth In ROCE To Persist
Sep 12Carl Zeiss Meditec (ETR:AFX) Seems To Use Debt Rather Sparingly
Aug 25Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Hit The Brakes
May 30Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Feb 27Carl Zeiss Meditec's (ETR:AFX) Returns Have Hit A Wall
Feb 08Here's Why We Think Carl Zeiss Meditec (ETR:AFX) Is Well Worth Watching
Dec 12Carl Zeiss Meditec (ETR:AFX) Has Some Way To Go To Become A Multi-Bagger
Nov 06If You Like EPS Growth Then Check Out Carl Zeiss Meditec (ETR:AFX) Before It's Too Late
Sep 06Investors Met With Slowing Returns on Capital At Carl Zeiss Meditec (ETR:AFX)
Aug 08Here's Why We Think Carl Zeiss Meditec AG's (ETR:AFX) CEO Compensation Looks Fair for the time being
May 21Why Carl Zeiss Meditec's (ETR:AFX) Shaky Earnings Are Just The Beginning Of Its Problems
May 18Capital Allocation Trends At Carl Zeiss Meditec (ETR:AFX) Aren't Ideal
Apr 28Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 19% Below Its Share Price
Mar 09How Should Investors Feel About Carl Zeiss Meditec's (ETR:AFX) CEO Remuneration?
Feb 16
What Type Of Shareholders Own The Most Number of Carl Zeiss Meditec AG (ETR:AFX) Shares?
Jan 30Rentabilidad de los accionistas
| AFX | DE Medical Equipment | Mercado DE | |
|---|---|---|---|
| 7D | -5.2% | -1.0% | 1.9% |
| 1Y | -16.2% | -5.0% | 4.6% |
Rentabilidad vs. Industria: Los resultados de AFX fueron inferiores a los de la industria German Medical Equipment, que obtuvo un rendimiento del -8.3% el año pasado.
Rentabilidad vs. Mercado: AFX obtuvo unos resultados inferiores a los del mercado German, que fue del -0.3% el año pasado.
Volatilidad de los precios
| AFX volatility | |
|---|---|
| AFX Average Weekly Movement | 4.2% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: El precio de las acciones de AFX ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de AFX (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1846 | 4,823 | Markus Weber | www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir |
Carl Zeiss Meditec AG opera como empresa de tecnología médica en Alemania, el resto de Europa, Norteamérica y Asia. Opera en dos segmentos, Oftalmología y Microcirugía. El segmento de Oftalmología ofrece productos y soluciones para el diagnóstico y tratamiento de enfermedades oculares crónicas, como ametropía (refracción), cataratas, glaucoma y trastornos renitales.
Resumen de fundamentos de Carl Zeiss Meditec AG
| Estadísticas fundamentales de AFX | |
|---|---|
| Capitalización bursátil | €8.40b |
| Beneficios(TTM) | €276.80m |
| Ingresos (TTM) | €2.09b |
30.3x
Ratio precio-beneficio (PE)4.0x
Ratio precio-ventas (PS)¿Está AFX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de AFX | |
|---|---|
| Ingresos | €2.09b |
| Coste de los ingresos | €893.14m |
| Beneficio bruto | €1.20b |
| Otros gastos | €924.07m |
| Beneficios | €276.80m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
Aug 06, 2024
| Beneficios por acción (BPA) | 3.09 |
| Margen bruto | 57.35% |
| Margen de beneficio neto | 13.22% |
| Ratio deuda/patrimonio | 7.2% |
¿Cómo se ha desempeñado AFX a largo plazo?
Ver rendimiento histórico y comparativa